Sharon Curran work email
- Valid
Sharon Curran personal email
- Valid
Board Advisory & Non-Executive Board Director Credentials Board-level relationships; Shareholders, Investors, Executives, Senior Management Team, Active and supporting Board & Executive Network. Experience in Governance, Strategy [ M&A, JV’s, Portfolio Prioritizations, Go-To- Market, Launch and Commercialization], Leadership [Succession Planning, Board Effectiveness, Organizational Structure, Culture and Integration] and Finance [ P&L Management, Audit, Compliance andSustainability] Global Strategy Development & Executive LeadershipSenior Executive / VP Global Marketing - top-level experience in leading high impact global marketing, commercialization + growth strategies. Strategic leadership and decision-making scrutiny for world class pharmaceutical corporations - AbbVie, Abbott Pharmaceuticals & Eli Lilly. Global Marketing, Commercialization & Capability Development. Full $USD Multi-Billion P&L responsibility. Driving sales growth + commercialization strategies at global, regional + country levels (favourable margin profiles) across multiple markets through strategic alliances, go-to-market launch planning, value proposition development, supply chain + marketing and sales force capability.Strategic Oversight & Risk GovernanceGovernance: Crisis Mgt, Audit & Risk, RemunerationOversight for therapeutic areas (Oncology, Neurology, Niche Specialities), Centres of Excellence, customer excellence, product launches, supply chain, global talent strategy + local market compliance. NED ROLES, COMMITTEES & AWARDSNon-Executive Director Board Member | MorphoSys AG, Circassia plc and Noden PharmaAudit & Risk Committee Member | MorphoSys AG and Circassia plcRemuneration Committee Chair | Circassia PLC Ethics & Compliance; Portfolio Strategy; Global Crisis Management | ABBVIE (US) President’s Awards (2011 & 2013)| ABBVIE (Global) LEADERSHIP DEVELOPMENTMSc Business Administration (Executive Management) Chartered Director Program | Institute of Directors (Ireland)Senior Executive, Talent & Leadership Programs Strategic Pharma Marketing; Innovation & EntrepreneurshipThought Leadership, Think Tanks + KOL networksAdvisory Panels, Industry Partners, Major VendorsBSc Biotechnology (R&D Placement, Asia)
-
Independent Non-Executive DirectorNorgineIreland
-
Independent Non Executive Board DirectorAbacus Medicine Oct 2024 - PresentKøbenhavn, Hovedstaden, DkThe Abacus Medicine Group supplies prescription medicine to thousands of customers across the world. The Group operates as four brands: Abacus Medicine, Pluripharm, Abacus Medicine Pharma Services and Originalis. Each brand has a distinct core capability. The Group employs >1.300 people across 9 Global locations. -
Independent Non-Executive DirectorNorgine Feb 2023 - PresentAmsterdam, Amsterdam, NlOn 15th December, 2022 – Norgine Europe B.V. (“Norgine”, the “Company”), a leading European specialty pharmaceutical company, announced that the Private Equity business within Goldman Sachs Asset Management has completed its acquisition of a majority stake in the Company. The deal closure is a key milestone in Norgine’s history, following over 110 years of family ownership by the Stein Family (who will continue to own a significant stake in the Company). With Goldman Sachs Asset Management as its key partner, Norgine is strongly positioned to deliver on its mission of bringing transformative medicines to market while purposefully putting patients at the heart of its strategy. The Company is focused on growth through advancing its existing portfolio of leading brands, developing and commercializing innovative pipeline products, and leveraging the Norgine platform through business development initiatives.Norgine has focused on building its fully integrated platform across Europe, Australia and New Zealand for more than 35 years and has grown consistently over that time. Today Norgine generates more than €500 million of sales annually. Its portfolio includes the iconic MOVICOL® brand with 25+ years’ heritage, a growing roster of promoted prescription products, and a portfolio of innovative pipeline products across multiple therapeutic areas.Norgine serves as a true specialty pharma platform, with a proven track record of developing, acquiring, and in-licensing assets while leveraging its integrated operations, which include a pan-European infrastructure and strong regulatory, market access, and launch capabilities.
-
Independent Non-Executive Board DirectorNiox® Feb 2018 - PresentOxford, England, GbCircassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR) is a world-class specialty pharmaceutical business focused on respiratory disease. The Company sells its novel, market-leading NIOX® asthma management products directly to specialists in the United States, United Kingdom, China and Germany, and in a wide range of other countries through its network of partners. In the United States, Circassia has a commercial collaboration with AstraZeneca in which it has the commercial rights to chronic obstructive pulmonary disease (COPD) treatments Tudorza® and Duaklir®. Circassia also has the US and Chinese commercial rights to the late-stage ventilator-compatible nitric oxide product AirNOvent. For more information please visit www.circassia.com.INDEPENDENT NON-EXECUTIVE BOARD MEMBERStrategic, commercial and operational leadership guidance to support the commercialization of respiratory products + globally launch of medical device assets into major strategic markets (focus on key markets). -
Independent Non-Executive Sv Board MemberMorphosys Ag May 2019 - Sep 2024Planegg, Bayern, DeNovartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash. MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 330 employees. More information at https://www.morphosys.com. -
Independent Non Executive Board DirectorNoden Pharma Oct 2020 - Oct 2022Dublin 2, IeAcquired by Lab X.O. Pharma -
Independent Non-Executive Board DirectorClinigen Group Apr 2021 - Apr 2022London, England, GbTRITON ACQUISITION OF CLINIGENClinigen plc, the global, specialist pharmaceutical services and products platform was acquired by a newly-formed company indirectly owned by the Triton Funds, Triley Bidco Limited. -
Vice-President, Global Marketing & CapabilityAbbvie 2014 - 2017North Chicago, Illinois, UsVP Global Marketing & Capability for a global innovation, research and biopharmaceutical manufacturing corporation (USD$ 28 billion turnover). Led global strategy for the Speciality Franchise Portfolio covering Neuroscience Neurology, Neonatology & Niche Therapeutic Areas. Full $USD Multi-Billion P&L responsibility, plus accountability for long-term growth plans (USD$ Multi-Billion targets by 2020).GLOBAL MARKETING & CAPABILITY DEVELOPMENTGained CEO / Executive Board approval (business case + long-term strategy)Commercialization Roadmap, Clinical Development, Financial PerformanceCrisis Management focus (prioritized certain countries + supply chain issues)Global growth (expansion), Market Development (existing + emerging markets)Value Propositions (Clinical Development, Market Access, Patient Outcomes)Global matrix leadership + talent pool (Senior Directors & 150+ Line Reports)Strategic Markets, Emerging Regions, Resource Optimization, Talent StrategiesCUSTOMER EXCELLENCE STRATEGYEstablished Global Launch Team (commercialization into new therapeutic areas)Global & Country go-to-market plans; new centralized model / Centres of ExpertisePricing, Market Access, Reimbursement, Regulatory, Supply Chain, CommercializationCreated new innovative Hospital + Patient Onboarding Centre of Excellence ModelPatient + Carer journey mapping, patient support program + appropriate outcomesKEY ACHIEVEMENTS & PERFORMANCERejuvenated neurology drug; strategic re-launch + impressive %CAGR 2Y growth Board approval - accelerated development of a non-invasive device (defined USP)Re-negotiated supply contracts for in-licensed products (grew Division margins)Improved transfer pricing for active ingredient + negotiated contract extensionsDelivered combined $USD Multi-Billion incremental sales with higher margins Led in-market team for strategic market + region (Board Member & SVP Operations) Won significant Government tenders (+ maintained key supply agreements) -
Senior Director, Global Marketing & Commercial OperationsAbbvie 2012 - 2014North Chicago, Illinois, UsCombined global P&L responsibility ($USD multi-billion sales) for Neurology & Endocrinology portfolios. Developed business cases - key investments in product development + strategic launches (global regions).GLOBAL MARKETING & COMMERCIALIZATION STRATEGYLed integrated global marketing, commercialization + growth strategiesLed cross-functional teams for the neurology portfolio + device developmentEvidence generation, patient support programs + in-field sales / operational plansAchieved impressive %CAGR 2Y generation (kept on target for peak sales target)Fully integrated neurology brand; won 2013 President’s Global Brand Team AwardProduct Development, Market Access, Supply Chain, Marketing, Regulatory & Legal STRATEGIC INITIATIVES & BUSINESS OPTIMIZATIONLed business optimization program to improve P&L performance of a mature brandSignificant bottom line improvements ($USD Millions across key strategic markets)Maintained sales revenues over a 5-year period for mature brand (growth + stability)Secured investment on key initiatives alongside sales force optimization (top markets)Generated business development, commercialization + re-investment opportunitiesIdentified key M&A targets for company or product acquisitions within niche segments Oversight for due diligence + market / competition analysis (M&A targets + evaluations)
-
Global Brand & Commercial Director (Anaesthesia)Abbott Laboratories 2009 - 2012Abbott Park, Illinois, UsGlobal Brand & Commercial Director for a Global Healthcare & Research Corporation; Discovery, Development & Manufacturing ($USD 27 billion turnover). Successfully stabilized 4-year decline (20% sales reduction) in mature markets (Europe, US & Canada) for a generic prescription brand (circa $USD 1 billion asset at peak). REJUVENATION & GROWTH STRATEGY (HIGH PERFORMANCE)Solved critical issues by developing a globally-led tender + contract strategy with highly differentiated brand value strategy to maintain top line sales. Led strategic alignment of emerging markets (China, Russia, India, Ukraine, NW Africa & Middle East). Increased top line sales (impressive double-digit CAGR increase) and reduced COGS (Cost of Goods) for priority brands (overall double-digit margin improvement). -
Divisional Head, Strategy & Operations (Ireland & Uk Affiliate)Eli Lilly & Co. (Irl) Ltd 2002 - 2008Indianapolis, Indiana, UsDivisional Head for a global pharmaceutical company specializing in R&D, Manufacturing + Commercial Operations ($USD 23 billion turnover). Led Strategic & Operational Plans (UK Board Approval). GROWTH STRATEGY (HIGH PERFORMANCE)Achieved highest uptake of new launches, double-digit growth. Exceeded challenging targets for 5 consecutive years + won recognition with EU & Global Company Awards for Best Launch in Europe of key products in 2003, 2005 & 2008 (measured by 1st year market share uptake). EARLY CAREER PROGRESSIONDivisional Head, Primary Care Strategy & Operations (Eli Lilly, UK) Group Marketing & Business Unit Manager (Eli Lilly, Ireland)Hospital Sales Specialist (Eli Lilly, Ireland);Hospital Sales Specialist (Novo Nordisk, Ireland)Medical Device Sales Representative (Med Labs, Ireland) -
Strategic Planning, Prozac Post-Patent Strategy Div MgtEli Lilly & Co. (Irl) Ltd Dec 1999 - Mar 2002Indianapolis, Indiana, UsProzac, Prozac Post-Patent Div Head:Brand Management / Sales/Marketing/Commercial Strategy Development & ImplementationStrategic Planning - Primary Care Div:
Sharon Curran Skills
Sharon Curran Education Details
-
Institute Of Directors (Iod)Chartered Director [Cdir] -
Trinity College Dublin(Management) Business Administration
-
Dublin City UniversityBiotechnology
-
Technological University DublinAssociate Of Institute Of Medical Laboratory Science
-
Irish Management Institute
Frequently Asked Questions about Sharon Curran
What company does Sharon Curran work for?
Sharon Curran works for Norgine
What is Sharon Curran's role at the current company?
Sharon Curran's current role is Independent Non-Executive Director.
What is Sharon Curran's email address?
Sharon Curran's email address is sh****@****ail.com
What schools did Sharon Curran attend?
Sharon Curran attended Institute Of Directors (Iod), Trinity College Dublin, Dublin City University, Technological University Dublin, Irish Management Institute.
What skills is Sharon Curran known for?
Sharon Curran has skills like Pharmaceutical Industry, Strategy, Product Launch, Pharmaceutical Sales, Sales Effectiveness, Management, Cross Functional Team Leadership, Strategic Planning, Oncology, Global Marketing, Market Access, Pharmaceutics.
Who are Sharon Curran's colleagues?
Sharon Curran's colleagues are Jamie Stephens, Steven Hunt, Daniela Meulemans-Rangel Maia, Lindsay Vye, Kelly Maher, Paula Mendes, Carine Bonfond.
Free Chrome Extension
Find emails, phones & company data instantly
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial